| Title | Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. | | Author(s) | Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD | | Institution | HIV Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC 27709, USA. svh31379@gsk.com | | Source | Lancet 2002 Mar 30; 359(9312):1121-2. | | MeSH | Adult
Aged
Anti-HIV Agents
Case-Control Studies
Continental Population Groups
Dideoxynucleosides
Drug Hypersensitivity
Female
Genetic Markers
HIV Infections
HIV-1
HLA-B Antigens
Humans
Male
Middle Aged
Polymorphism, Genetic
Predictive Value of Tests
Research Support, Non-U.S. Gov't
Retrospective Studies
Reverse Transcriptase Inhibitors
Sensitivity and Specificity
Tumor Necrosis Factor-alpha
Variation (Genetics)
| | Abstract | Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection. We did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B associated with hypersensitivity reactions. HLA-B57 was present in 39 (46%) of 84 patients versus four (4%) of 113 controls (p<0 small middle dot0001). However, because of low numbers of women and other ethnic groups enrolled, these findings relate largely to white men. The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 11943262 |
|
